True. $8.6m annualised NPAT with 133m shares on issue implies 6.5c EPS and current run rate should be in excess of this. Hopefully cash flow improves and starts to reflect profit.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025